Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Delayed Nasdaq 04:00:00 2023-10-02 pm EDT Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
74.10 USD -1.12% -0.98% -13.69%

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History : Analyst Recommendations

6161e0041e1ae848b25de3d821cc9.fOTYg07zkd8o7uqDFIaGOixkDWu23cqiLHFGheSsb70.TtePyBSiqYl_nKmwV9zBa0EpXTiB747GYT0v9andKYgOvIfBNLmom36IiQ~08c9243633df637b16bf82e1fcd68547
BofA Securities Upgrades Gilead Sciences to Buy From Neutral, Adjusts Price Target to $95 From $88 MT
HSBC Initiates Gilead Sciences With Reduce Rating, Price Target is $71 MT
ANALYST RECOMMENDATIONS : Amgen, Biogen, Broadcom, Fedex, Salesforce... ZB
UBS Adjusts Gilead Sciences Price Target to $84 From $88, Maintains Neutral Rating MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $85 From $84, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $88 From $86, Maintains Equal-Weight Rating MT
RBC Lifts Price Target on Gilead Sciences to $84 From $83, Maintains Sector Perform Rating MT
Piper Sandler Lowers Gilead Sciences' Price Target to $100 From $105, Overweight Rating Kept MT
Barclays Adjusts Gilead Sciences' Price Target to $80 From $81, Keeps Equalweight Rating MT
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $80 From $85, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Gilead Sciences to $81 From $84, Maintains Equalweight Rating MT
RBC Lowers Gilead Sciences' Price Target to $83 From $88, Keeps Sector Perform Rating MT
BMO Capital Upgrades Gilead Sciences to Outperform From Market Perform, Adjusts Price Target to $100 From $90 MT
ANALYST RECOMMENDATIONS : Amazon, Amdocs, Gilead, MacFarlane, TUI... ZB
UBS Adjusts Gilead Sciences Price Target to $88 From $91, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $86 From $85, Maintains Equal-Weight Rating MT
Piper Sandler Assumes Gilead Sciences at Overweight With $105 Price Target MT
RBC Capital Adjusts Price Target on Gilead Sciences to $88 From $87, Maintains Sector Perform Rating MT
ANALYST RECOMMENDATIONS : Antofagasta, Capricorn Energy, Gilead, Intel, Old Dominion... ZB
UBS Adjusts Gilead Sciences Price Target to $91 From $90, Maintains Neutral Rating MT
Morgan Stanley Raises Price Target on Gilead Sciences to $85 From $81, Maintains Equalweight Rating MT
RBC Capital Adjusts Gilead Sciences Price Target to $87 From $86, Maintains Sector Perform Rating MT
RBC Trims Price Target on Gilead Sciences to $86 From $87, Maintains Sector Perform Rating MT
Mizuho Securities Adjusts Gilead Sciences Price Target to $101 From $88, Maintains Buy Rating MT
UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.10USD
Average target price
91.36USD
Spread / Average Target
+23.30%
High Price Target
116.00USD
Spread / Highest target
+56.55%
Low Price Target
71.00USD
Spread / Lowest Target
-4.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

BofA Securities
HSBC
UBS
Goldman Sachs
Morgan Stanley
RBC Capital Markets
Piper Sandler
Barclays
Cantor Fitzgerald
BMO Capital
Mizuho Securities
SVB Securities LLC
Wells Fargo Securities
Oppenheimer
Cowen
Maxim
Truist Securities
JPMorgan Chase
Argus
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK Elmar Kraus
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer